Lyra Therapeutics Inc
NASDAQ:LYRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Haima Automobile Co Ltd
SZSE:000572
|
CN |
Lyra Therapeutics Inc
Depreciation & Amortization
Lyra Therapeutics Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lyra Therapeutics Inc
NASDAQ:LYRA
|
Depreciation & Amortization
$510k
|
CAGR 3-Years
-23%
|
CAGR 5-Years
76%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Depreciation & Amortization
$7.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Depreciation & Amortization
$4B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
27%
|
|
|
Pfizer Inc
NYSE:PFE
|
Depreciation & Amortization
$6.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Depreciation & Amortization
$5.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Depreciation & Amortization
$2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
Lyra Therapeutics Inc
Glance View
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-05-01. The firm is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.
See Also
What is Lyra Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
510k
USD
Based on the financial report for Sep 30, 2025, Lyra Therapeutics Inc's Depreciation & Amortization amounts to 510k USD.
What is Lyra Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
76%
Over the last year, the Depreciation & Amortization growth was 25%. The average annual Depreciation & Amortization growth rates for Lyra Therapeutics Inc have been -23% over the past three years , 76% over the past five years .
